Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-κB (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen

Journal of Immunology

Volumn 171, Issue 8, 2003, Pages 4121-4130

  Wiethe, Carsten ^a,b,c,d   Dittmar, Kurt ^a   Doan, Tracy ^b,c   Lindenmaier, Werner ^a   Tindle, Robert ^b,c  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; CD40 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR ANTIGEN; TUMOR VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CELL FUNCTION; CELL SURFACE; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; EMBRYO; HUMAN; HUMAN CELL; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; UTERINE CERVIX CARCINOMA; WART VIRUS;

EID: 0141889148     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.8.4121     Document Type: Article

References (51)

1. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
2. Rosenberg, S. A. 2001. Progress in human tumour immunology and immunotherapy. Nature 411:380.
3. Pardoll, D. M. 2002. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2:227238.
4. Hurwitz, A. A., Kwon, E. D., and A. van Elsas. 2000. Costimulatory wars: the tumour menace. Curr. Opin. Immunol. 12:589.
5. Green, E. A., and R. A. Flavell. 1999. TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation. J. Exp. Med. 189:1017.
6. + T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. J. lmmunol. 170:1797.
7. Roy, M., A. Aruffo, J. Ledbetter, P. Linsley, M. Kehry, and R. Noelle. 1995. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur. J. Immunol. 25:596.
8. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747.
9. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler. E. Kampgen, N. Romani, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184:741.
10. Chen, A. I., A. J. McAdam, J. E. Buhlmann, S. Scott, M. L. Lupher, Jr., E. A. Greenfield, P. R. Baum, W. C. Fanslow, D. M. Calderhead, G. J. Freeman, and A. H. Sharpe. 1999. Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity 11:689.
11. + T cells. J. Exp. Med. 185:2133.
12. Wong, B. R., R. Josien, S. Y. Lee, B. Sauter, H. L. Li, R. M. Steinman, and Y. Choi. 1997. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186:2075.
13. Josien, R., H. L. Li, E. Ingulli, S. Sarma, B. R. Wong, M. Vologodskaia, R. M. Steinman, and Y. Choi. 2000. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J. Exp. Med. 191:495.
14. Tindle, R. W., S. Croft, K. Herd, K. Malcolm, A. F. Geczy, T. Stewart, and G. J. Fernando. 1995. A vaccine conjugate of "ISCAR" immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants. Clin. Exp. Immunol. 101:265.
15. Doan, T., M. Chambers, M. Street, G. J. Fernando, K. Herd, P. Lambert, and R. Tindle. 1998. Mice expressing the E7 oncogene of HPV 16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes. Virology 244:352.
16. Feltkamp, M. C., H. L. Smits, M. P. Vierboom, R. P. Minnaar, B. M. de Jongh, J. w. Drijfnout, J. ter Schegget, C. J. Melief, and W. M. Kast. 1993. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:2242.
17. Shi, W., P. Bu, J. Liu, A. Polack, S. Fisher, and L. Qiao. 1999. Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J. Virol. 73:7877.
18. Armitage, R. J., W. C. Fanslow. L. Strockbine, T. A. Sato, K. N. Clifford, B. M. Macduff, D. M. Anderson, S. D. Gimpel, T. Davis-Smith, C. R. Maliszewski, et al. 1992. Molecular and biological characterization of a murine ligand for CD40. Nature 357:80.
19. Prevec, L., B. S. Christie, K. E. Laurie, M. M. Bailey, F. L. Graham, and K. L. Rosenthal. 1991. Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. J. Acquired Immune Defic. Syndr. 4:568.
20. Tindle, R. W., J. A. Smith, H. M. Geysen, L. A. Selvey, and I. H. Frazer. 1990. Identification of B epitopes in human papillomavirus type 16 E7 open reading frame protein. J. Gen. Virol. 71:1347.
21. Lutz, M. B., N. Kukutsch, A. L. Ogilvie, S. Rossner, F. Koch, N. Romani, and G. Schuler. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223:77.
22. Porgador, A., and E. Gilboa. 1995. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255.
23. + T cells using an ELISPOT assay. J. Immunol. Methods 181:45.
24. Wiethe, C., K. Dittmar, T. Doan, W. Lindenmaier, and R. W. Tindle. 2003. Provision of 4-1BBL enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J. Immunol. 170:2912.
25. Josien, R., B. R. Wong, H. L. Li, R. M. Steinman, and Y. Choi. 1999. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J. Immunol. 162:2562.
26. Hurtado, J. C., S. H. Kim, K. E. Pollok, Z. H. Lee, and B. S. Kwon. 1995. Potential role of 4-1BB in T cell activation comparison with the costimulatory molecule CD28. J. Immunol. 155:3360.
27. DeBenedette, M. A., T. Wen, M. F. Bachmann, P. S. Ohashi, B. H. Barber, K. L. Stocking. J. J. Peschon, and T. H. Watts. 1999. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J. Immunol. 163:4833.
28. Viola, A., and A. Lanzavecchia. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273:104.
29. Celluzzi, C. M., and L. D. Falo, Jr. 1998. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol. 160:3081.
30. Arthur, J. F., L. H. Butterfield, M. D. Roth, L. A. Bui, S. M. Kiertscher, R. Lau, S. Dubinett, J. Glaspy, W. H. McBride, and J. S. Economou. 1997. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4:17.
31. De Bruijn, M. L., D. H. Schuurhuis, M. P. Vierboom, H. Vermeulen, K. A. de Cock, M. E. Ooms, M. E. Ressing, M. Toebes, K. L. Franken, J. W. Drijfhout, et al. 1998. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res. 58:724.
32. Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells. B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87.
33. + lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J. Virol. 73:5402.
34. Kaufmann. A. M., J. Nieland, M. Schinz, M. Nonn, J. Gabelsberger, H. Meissner, R. T. Muller, I. Jochmus, L. Gissmann, A. Schneider, and M. Durst. 2001. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int. J. Cancer 92:285.
35. Kirk, C. J., and J. J. Mule. 2000. Gene-modified dendritic cells for use in tumor vaccines. Hum. Gene. Ther. 11:797.
36. Tillman, B. W., T. L. Hayes, T. D. DeGruijh, J. T. Douglas, and D. T. Curiel. 2000. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res. 60:5456.
37. Ludewig, B., K. McCoy, M Pericin, A. F. Ochsenbein, T. Dumrese, B. Odermatt, R. E. Toes, C. J. Melief, H. Hengartner, and R. M. Zinkernagel. 2001. Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J. Immunol. 166:3678.
38. Hirschowitz, E. A., J. D. Weaver, G. E. Hidalgo, and D. E. Doherty. 2000. Murine dendritic cells infected with adenovirus vectors show signs of activation. Gene Ther. 7:1112.
39. Theill, L. E., W. J, Boyle, and J. M. Penninger, 2002. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20:795.
40. Anderson, D. M., E. Maraskovsky, W. L. Billingsley, W. C. Dougall, M. E. Tometsko, E. R. Roux, M. C. Teepe, R. F. DuBose, D. Cosman, and L. Galibert, 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175.
41. Wong, B. R., D. Besser, N. Kim, J. R. Arron, M. Vologodskaia, H. Hanafusa, and Y. Choi. 1999. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell 4:1041.
42. Bachmann, M. F., B. R. Wong, R. Josien, R. M. Steinman, A. Oxenius, and Y. Choi. 1999. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J. Exp. Med. 189:1025.
43. Melero, I., N. Bach, K. E. Hellstrom, A. Aruffo, R. S. Mittler, and L. Chen. 1998. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur. J. Immunol. 28:1116.
44. + T cell functions. J. Exp. Med. 183:2209.
45. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. Van Kooten, I. Durand, and J. Banchereau. 1994. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180:1263.
46. Fernando. G. J., T. J. Stewart, R. W. Tindle, and I. H. Frazer. 1998. Th2-type CD4-cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. J. Immunol. 161:2421.
47. Cannons, J. L., P. Lau, B. Ghumman, M. A. DeBenedette, H. Yagita, K. Okumura, and T. H. Watts. 2001. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J. Immunol. 167:1313.
48. van Driel, W. J., M. E. Ressing, G. G. Kenter, R. M. Brandt, E. J. Krul, A. B. van Rossum, E. Schuuring, R. Offringa, T. Bauknecht, A. Tamm-Hermelink. et al. 1999. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer 35:946.
49. Borysiewicz, L. K., A. Fiander, M. Nimako, S. Man, G. W. Wilkinson, D. Westmoreland, A. S. Evans, M. Adams, S. N. Stacey, M. E. Boursnell, et al. 1996. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523.
50. Herbert, R. A., A. Liem, H. Pitot, and P. F. Lambert. 1996. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J. Virol. 70:1873.
51. Frazer, I. H., D. M. Lieppe, L. A. Dunn, A. Liem, R. W. Tindle, G. J. Fernando, W. C. Phelps, and P. F. Lambert. 1995. Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease. Cancer Res. 55:2635.